

# Langerhans cell histiocytosis (LCH): treatment protocol of the first international study

|                                        |                                                   |                                                                                                   |
|----------------------------------------|---------------------------------------------------|---------------------------------------------------------------------------------------------------|
| <b>Submission date</b><br>01/07/2001   | <b>Recruitment status</b><br>No longer recruiting | <input type="checkbox"/> Prospectively registered<br><input type="checkbox"/> Protocol            |
| <b>Registration date</b><br>01/07/2001 | <b>Overall study status</b><br>Completed          | <input type="checkbox"/> Statistical analysis plan<br><input checked="" type="checkbox"/> Results |
| <b>Last Edited</b><br>01/02/2012       | <b>Condition category</b><br>Cancer               | <input type="checkbox"/> Individual participant data                                              |

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr - -

**Contact details**  
UKCCCR Register Co-ordinator  
MRC Clinical Trials Unit  
222 Euston Road  
London  
United Kingdom  
NW1 2DA

## Additional identifiers

**Protocol serial number**  
LCH 9103

## Study information

**Scientific Title**

**Study objectives**  
Not provided at time of registration

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Primary study design**

Interventional

**Study design**

Randomised controlled trial

**Study type(s)****Health condition(s) or problem(s) studied**

Lymphoma (non-Hodgkin's)

**Interventions**

1. Regimen A: Chemotherapy, vinblastine with high dose methyl prednisolone
2. Regimen B: Chemotherapy, etoposide with high dose methyl prednisolone

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Chemotherapy drugs

**Primary outcome(s)**

Not provided at time of registration

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

31/12/1999

## **Eligibility**

**Key inclusion criteria**

1. Definitive diagnosis of multi-system Langerhans cell histiocytosis
2. Age under 18 years
3. No prior treatment for Langerhans cell histiocytosis

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Child

**Upper age limit**

18 Years

**Sex**

**Key exclusion criteria**

Not provided at time of registration

**Date of first enrolment**

01/01/1991

**Date of final enrolment**

31/12/1999

## **Locations**

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

UKCCCR Register Co-ordinator

London

United Kingdom

NW1 2DA

## **Sponsor information**

**Organisation**

Cancer Research UK (CRUK) (UK)

**ROR**

<https://ror.org/054225q67>

## **Funder(s)**

**Funder type**

Charity

**Funder Name**

Cancer Research UK

**Alternative Name(s)**

CR\_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Other non-profit organizations

**Location**

United Kingdom

**Funder Name**

United Kingdom Children's Cancer Study Group (UKCCSG)

## Results and Publications

**Individual participant data (IPD) sharing plan****IPD sharing plan summary****Study outputs**

| Output type                     | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---------------------------------|---------|--------------|------------|----------------|-----------------|
| <a href="#">Results article</a> | results | 01/05/2001   |            | Yes            | No              |